Endocrinology Expert Witness for Medical Malpractice: How Attorneys and Insurers Choose

Board certification is the baseline, not the finish line. Certification from the American Board of Internal Medicine in Endocrinology, Diabetes, and Metabolism confirms competency across the specialty — but many malpractice cases turn on narrower clinical territory, such as hormone optimization, compounded therapies, or regenerative medicine, where general training may not be enough.

The stronger question is whether the expert has active clinical experience in the specific treatment at issue. A board-certified endocrinologist who regularly manages testosterone replacement therapy, prescribes peptides, or works in settings that use AI-assisted clinical decision tools carries significantly more weight than one who does not.

A peer-reviewed publication record establishes that the expert's opinions are grounded in recognized science, not personal preference. When opposing counsel challenges methodology under Daubert or similar standards, a PubMed-indexed record in the relevant area gives the court a verifiable foundation.

It also signals that the expert can explain complex endocrine physiology in writing with precision — exactly what a defensible written opinion requires. An expert who has never written for peer review is harder to defend when their reasoning is put under the microscope.

A strong expert report identifies the applicable standard of care with specificity, maps the clinical record to that standard, explains the deviation — or absence of one — in plain language, and connects causation through scientific reasoning rather than bare assertion.

Vague conclusions, unsupported claims, and opinions that shift between the written report and deposition testimony are exactly what opposing counsel will exploit. The report needs to hold its shape from submission through cross-examination.

Generalist directories like SEAK and JurisPro maintain searchable databases of credentialed professionals who have listed themselves as available for expert work. They are useful for generating names quickly, but the directory itself does not vet opinions, review clinical records, or guarantee that a listed expert has active experience in the specific area your case requires.

You are essentially browsing a phonebook. The quality of the opinion depends entirely on the individual you select and your own due diligence.

Referral brokers like IMS Legal Strategies and Homestead Experts go a step further by matching cases to experts and managing the administrative side of the engagement — but that service has a cost. Broker arrangements typically add a 30 to 40 percent markup over the expert's base rate, meaning you are paying a significant premium for matching and coordination, not for deeper clinical analysis.

Brokers also do not write or vet the opinion itself. The substantive work still rests with the individual expert, and visibility into how that expert was selected may be limited to the broker's matching criteria.

A specialist medicolegal practice built around a single board-certified subspecialist works differently. The attorney engages the expert directly, the record review and written opinion come from the same clinician who will testify, and there is no intermediary markup on the expert's time.

hormon.ai is structured this way. Every engagement is handled by Dr. Fady Hannah-Shmouni, a board-certified endocrinologist whose subspecialty depth covers hormone therapy, peptides, anabolic steroids, regenerative medicine, and AI-assisted clinical settings. Because the same physician who reviewed the records will be in the witness box, the opinion is built to withstand cross-examination from the start.

TRT cases often turn on narrow questions: Was the patient appropriately screened before initiation? Were testosterone levels monitored at the right intervals? Was the dose adjusted in response to adverse signs? Were contraindications — such as polycythemia or elevated cardiovascular risk — properly evaluated?

A generalist expert may know the broad principles but lack the clinical granularity to hold up when opposing counsel presses on specific protocols, lab thresholds, or the standard of care in a hormone optimization setting versus a traditional endocrinology clinic.

Peptide cases are among the most technically complex in current malpractice litigation. Many peptides used in clinical settings — BPC-157, CJC-1295, ipamorelin — are compounded and exist outside standard FDA-approved labeling. The standard of care questions are genuinely contested, and an expert who cannot articulate the clinical rationale, the compounding pharmacy landscape, and the applicable regulatory framework will struggle under deposition.

Cases involving compounded hormones, off-label GLP-1 use, or growth hormone secretagogues require an expert who has actually worked in this clinical space — not one who has simply reviewed a literature summary.

An emerging category of endocrinology malpractice involves AI tools embedded in clinical workflows — for diagnosis, dosing recommendations, or patient monitoring. When an AI-assisted decision contributes to patient harm, the liability questions become layered: Was the clinician's reliance on the AI output reasonable? Did the tool meet the applicable standard of care at the time? Was the outcome attributable to the AI recommendation or to the clinician's independent judgment?

This area requires an expert who understands both endocrine physiology and how agentic AI systems function in clinical settings — a combination very few expert witnesses can credibly offer.